OncoMatch/Clinical Trials/NCT07188441
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
Is NCT07188441 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Teniposide for gct.
Treatment: Teniposide — This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases. The main objective is to evaluate the safety and efficacy of teniposide combined with cisplatin in the treatment of newly diagnosed central malignant germ cell tumors, and to conduct drug monitoring on subjects to explore potential biomarkers for predicting therapeutic efficacy. It is expected to ultimately achieve the goal of prolonging the overall survival of patients, while providing more guidance for the screening of the best treatment population and biological predictive markers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Testicular Germ Cell Tumor
Prior therapy
Cannot have received: anti-cancer experimental treatment
Patients undergoing any other anti-cancer experimental treatment
Lab requirements
Blood counts
Absolute neutrophil ≥1.0×10^9/L; Platelet ≥100.0×10^9/L
Kidney function
Estimated glomerular filtration rate ≥ 70 mL/min/1.73 m² or normal serum creatinine (Cr)
Liver function
Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal; total bilirubin ≤1.5×Upper limit of normal
Absolute neutrophil ≥1.0×10^9/L; Platelet ≥100.0×10^9/L; Aspertate aminotransferase and alanine aminotransferase ≤2.5×Upper limit of normal; total bilirubin ≤1.5×Upper limit of normal; Estimated glomerular filtration rate ≥ 70 mL/min/1.73 m² or normal serum creatinine (Cr)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify